The IgGs were discovered from a na?ve human library of scFvs and had specificity to dendrotoxins from (the black mamba). These undertakings revolutionized envenoming therapy and have saved innumerous patients worldwide during Ridinilazole the last 100 years. This review describes in detail the above-mentioned historical events surrounding the discovery and the application of serum therapy for envenomings, as well as it provides an overview of important developments and scientific breakthroughs that were of importance for antibody-based therapies in general. This begins with discoveries concerning the characterization of antibodies, including the events leading up to the elucidation of the antibody structure. These discoveries further Ridinilazole paved the way for other milestones in antibody-based therapies, such as the introduction of hybridoma technology in 1975. Hybridoma technology enabled the expression and isolation of monoclonal antibodies, which in turn formed the basis for the development of phage display technology and transgenic mice, which can be harnessed to directly obtain fully human monoclonal antibodies. These developments were driven by the ultimate goal of producing potent neutralizing monoclonal antibodies with optimal pharmacokinetic properties and low immunogenicity. This review then provides an outline of the most recent achievements in antivenom research, which include the application of new biotechnologies, the development of the first human monoclonal antibodies that can Rabbit Polyclonal to VAV3 (phospho-Tyr173) neutralize animal toxins, and efforts toward creating fully recombinant antivenoms. Lastly, future perspectives in the field of envenoming therapies are discussed, including rational engineering of antibody cross-reactivity and the use of oligoclonal antibody mixtures. Keywords: envenoming therapy, antivenom, antibodies, antiserum, hybridoma technology, phage display, recombinant antivenom, antivenom history Introduction The discovery of serum therapy has paved the way for many human therapies, including envenoming therapy. Thanks to ingenious experimentation performed more than 120 years ago, several antivenoms are available for treating accidents Ridinilazole caused by venomous animals (1). Current antivenoms are heterologous and polyclonal in nature, as they are still manufactured via hyperimmunization of large domesticated animals, such as horses, sheep, donkeys, or camels (2). However, over more than one century of antivenom production, many important scientific discoveries and development of new technology have helped improve antivenom manufacture, as well as brought opportunities for developing fundamentally novel antivenom products (e.g., the discovery of antibody and DNA structures, hybridoma technology, polymerase chain reaction (PCR), recombinant expression of antibodies, and phage display technology). Therefore, several researchers worldwide are currently working towards improving Ridinilazole the manufacture and quality of both plasma-derived and non-plasma-derived antivenoms. This review presents a historical perspective of the main discoveries (Figure 1) that have impacted or Ridinilazole may impact the development and manufacture of antivenoms. Open in a separate window Figure 1 Antivenom history timeline. The timeline presents the most important discoveries related to antivenom research and development, including groundbreaking discoveries within immunology (years in purple) and molecular biology (years in green). The discoveries awarded with the Nobel Prize are indicated with the Alfred Nobel medal, but does not mean that all the researchers involved were laureated with the prize. *Gene modification discovery in mice was awarded with the Nobel Prize, and not the generation of fully human antibodies in transgenic mice. The Origin of Serum Therapy The use of serum therapy began in 1890 when Emil von Behring and Shibasaburo Kitasato published their groundbreaking paper on tetanus immunity (3). Briefly summarized, their experiments consisted of (1) immunizing rabbits against an inactivated culture containing virulent culture in the same group of mice (Figure 2A). With their findings, Behring and Kitasato put forward the theory of humoral immunity, proposing that a mediator in the blood could neutralize a foreign antigen, which was mentioned in their paper as neutralization with their serum, which was due to the IgM-nature of the primary immune response they induced with their approach, whereas the serum produced with Calmette’s immunization protocol over several weeks resulted in IgG format antibodies that were able to protect (29). In spite of their simultaneous publication of the principle of immunization with snake venom and use of their serum as an antivenom, only Calmette receives recognition for this discovery nowadays. By 1895, Calmette had produced anti-cobra serum in.